-
Jan 17, 2025 | 
healio.com | Scott Buzby |Richard Smith |Christie M. Ballantyne
The year in lipids: Progress in Lp(a) management and a blow to the ‘HDL hypothesis’• Topics included triglyceride and lipoprotein(a) management as well as another setback to the “HDL hypothesis.”In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention of major adverse CV events. At the Cardiometabolic Health Congress in October, Christie M.
-
Oct 17, 2024 | 
healio.com | Scott Buzby |Erik Swain |Keith C. Ferdinand |Christie M. Ballantyne
You've successfully added CHD/Prevention to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Speakers highlighted recent regulatory moves in the areas of hypertension, lipids and diabetes.
-
Oct 16, 2024 | 
healio.com | Scott Buzby |Katie Kalvaitis |Christie M. Ballantyne
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The Cardiometabolic Health Congress takes place Oct. 17-19 in Boston. The meeting will feature four main sessions with presentations that span the field of cardio-kidney-metabolic care and more.
-
Jun 7, 2024 | 
healio.com | Erik Swain |Richard Smith |Christie M. Ballantyne
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Much of the cardiology field is focused on treating end-stage heart disease, but prevention is more important. The National Lipid Association (NLA) is prioritizing research and education on prevention of CVD.
-
Jun 3, 2024 | 
healio.com | Erik Swain |Richard Smith |Christie M. Ballantyne
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Plozasiran demonstrated durable improvement in triglycerides, APOC3 and other lipid parameters for patients with very high triglycerides. The drug also showed benefit in familial chylomicronemia syndrome.
-
May 29, 2024 | 
healio.com | Scott Buzby |Richard Smith |Christie M. Ballantyne
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The National Lipid Association Scientific Sessions will be held May 30-June 2 in Las Vegas. Lipoprotein(a) and “cardio-rheumatology” are expected to be among the hot topics from the 4-day meeting.
-
May 29, 2024 | 
healio.com | Erik Swain |Richard Smith |Christie M. Ballantyne |Robert S. Rosenson
You've successfully added CHD/Prevention to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Two small interfering RNA therapies lowered triglyceride levels in patients with mixed hyperlipidemia at 24 weeks. They also lowered non-HDL and apolipoprotein B.
-
Apr 6, 2024 | 
healio.com | Regina Schaffer |Katie Kalvaitis |C. Michael Gibson |Christie M. Ballantyne
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Four weekly infusions of apolipoprotein A-I did not reduce risk for heart-related events in the setting of acute MI. The therapy was well tolerated.
-
Apr 2, 2024 | 
healio.com | Erik Swain |Richard Smith |Christie M. Ballantyne
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Lp(a) represents a “continuous gradient of risk” for heart disease and should be measured in adults at least once. Lipid-lowering therapies are appropriate for many patients with high Lp(a).
-
Nov 27, 2023 | 
hcplive.com | Keith C. Ferdinand |Erin D. Michos |Christie M. Ballantyne |Mary McGowan |Payal Kohli
Keith C. Ferdinand, MD, FACC, FAHA, FNLA: I’m going to give each of you about a minute or so to give what we call a take-home message: a clinical pearl for the physicians, nurse practitioners, physician assistants, [and] pharmacists who may be listening, something that will motivate them to do better. We’ve heard from the Family Heart Foundation that we’re not recognizing these patients early enough and that those patients at high risk are not getting high-intensity statin.
